SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Nov 14, 2019
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: Nov. 14, 2019 · CIK: 0001372514 · Accession: 0001104659-19-064375
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234255
Letter
EyeGate Pharmaceuticals, Inc.
271 Waverley Oaks Road, Suite 108
Waltham, Massachusetts 02452
November 14, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: EyeGate Pharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-3
File No. 333-234255
Request for Acceleration
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the Registration Statement on Form S-3 (File No. 333-234255) (the “Registration Statement”) of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on November 18, 2019, or as soon as practicable thereafter.
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Robert A. Petitt of Burns & Levinson LLP at (617) 345-3361 and that such effectiveness also be confirmed in writing.
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (781) 881-2112 or our attorney, Robert A. Petitt at the number above. Thank you for your assistance.
Very truly yours,
EYEGATE PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
EyeGate Pharmaceuticals, Inc.
271 Waverley Oaks Road, Suite 108
Waltham, Massachusetts 02452
November 14, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: EyeGate Pharmaceuticals, Inc. (the “Company”)
Registration Statement
on Form S-3
File No. 333-234255
Request for Acceleration
Ladies
and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the Company respectfully requests acceleration by the Securities and Exchange Commission (the “Commission”)
of the effective date of the Registration Statement on Form S-3 (File No. 333-234255) (the “Registration Statement”)
of the Company. The Company respectfully requests that the Registration Statement become effective as of 4:30 p.m., Washington,
D.C. time, on November 18, 2019, or as soon as practicable thereafter.
The Company respectfully requests that it
be notified of such effectiveness by a telephone call to Robert A. Petitt of Burns & Levinson LLP at (617) 345-3361 and that
such effectiveness also be confirmed in writing.
If you have any further questions or comments,
or if you require any additional information, please contact the undersigned by telephone at (781) 881-2112 or our attorney, Robert
A. Petitt at the number above. Thank you for your assistance.
Very truly yours,
EYEGATE PHARMACEUTICALS, INC.
By:
/s/ Sarah Romano
Name:
Sarah Romano
Title:
Chief Financial Officer
cc: Stephen D. Brook, Esq., Burns & Levinson LLP
Robert A. Petitt, Esq., Burns
& Levinson LLP